Absorption of Estrogens From Vaginal Creams

Rigg, Lee A.; Hermann, Harold W.; Yen, S. S. C.

doi:10.1097/00006254-197806000-00018

Cited by 5 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By the end of the 14th day of treatment with the conjugated vaginal cream, the estrone plasma level was approximately 4 times the physiological level of 40 pg/ml and the estradiol plasma level was well below the physiological level of 70 pg/ml.2 However, subjects in the estradiol-cream group had a mean estradiol level of 70.4 pg/ml and the estrone level near the premenopausal physiological plasma level. This agrees with the results of the single-dose study by Riggs et al 6 An interesting correlation of the percent of improvement and estradiol and estrone plasma levels at the end of the 2-wk treatment was observed in the estradiol group. Close examination of the data in this group at baseline showed no relationship among number or severity of symptoms, number of postmenopausal years, or baseline estrone or estradiol plasma levels to the degree of severity of symptoms or improvement after therapy .…”

Section: Discussionsupporting

confidence: 92%

Efficacy of estradiol vaginal cream in postmenopausal women

Dickerson

Bressler

Christian

et al. 1979

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

In a recent comparison of estradiol and conjugated estrogen creams,6 single intravaginal doses of both estrogens were well absorbed by postmenopausal women. Only the estradiol cream led to plasma estrone and estradiol levels of premenopausal women. Symptoms of menopause have largely been attributed to a decrease in estrogen secretion, a normal process of aging. While the question of the best mode of therapy is controversial, physiological replacement would be a logical choice for postmenopausal vasomotor symptoms and vaginal mucosa atrophy. Our study was conducted to determine estrogen levels achieved after nightly vaginal administration of estradiol cream for 14 days and to evaluate it in the treatment of postmenopausal signs and symptoms. Materials and methodsThe patients were postmenopausal for at least 1 yr and had vasomotor or vaginal symptoms of estrogen deficiency. They received no estrogen or medications which could interfere with estrogen assays for at least 1 mo prior to the study. The study followed a double-blind parallel design. On a random assignment 20 patients received estradiol vaginal cream 0.01% (0.2 mg 17,8-estradiol) and 10 patients received conjugated estrogen cream (1.25 mg conjugated estrogens). An intravaginal dose of 2 gm of cream was administered at bedtime for 14 consecutive days. Patients returned for evaluation of their therapy on day 8 (12 hr after their seventh dose) and day 15 (12 hr after their fourteenth dose).Efficacy of the creams was measured by the maturation indices of the vaginal epithelium cells and severity ratings of vaginal and vasomotor symptoms at each visit. Patients were asked to record the number of vasomotor symptoms per day, and the severity of the hot flashes, 502

show abstract

Section: Discussionsupporting

confidence: 92%

Efficacy of estradiol vaginal cream in postmenopausal women

Dickerson

Bressler

Christian

et al. 1979

Clin Pharma and Therapeutics

View full text Add to dashboard Cite

show abstract

“…These symptoms have been shown to respond to both vaginal 62 and systemic ERT, 63 , 64 although with systemic treatment, benefit may not be seen for up to 12 to 18 months following initiation of therapy 65 . Vaginal estrogens have been shown to be well absorbed systemically, 66 , 67 although in very low doses (0.3 mg of conjugated estrogens or less), absorption may be reduced 68 . Vaginal changes respond to local applications of estrogen‐containing creams in daily doses as low as 0.1 mg 62 .…”

Section: Therapeutic and Preventive Uses Of Hrt/ertmentioning

confidence: 99%

Perimenopausal hormone replacement therapy Review of the literature

Lichtman¹

1991

Journal of Nurse-Midwifery

View full text Add to dashboard Cite

“…Topical hormone administration for the treatment of FI could be an interesting possibility to improve life quality of a large group of women, considering that it is safe, inexpensive and easy to apply. It is frequently applied in the vagina [8,9]. Notwithstanding this, there is no literature describing its use in the anal mucosa.…”

Section: Introductionmentioning

confidence: 99%